Due to the recommendations of local government, NHF's New York City staff will be working remotely until further notice. We will continue to work to serve the bleeding disorders community during this time.
Takeda responded to the HFA-NHF letter late yesterday regarding the recall of two lots of VONVENDI von Willebrand factor.
The National Hemophilia Foundation will continue to monitor the rapidly changing situation regarding COVID-19 and provide regular updates to our community.
XINITY® is currently indicated for the control and prevention of bleeding episodes and for perioperative management in adults and children, 12 years of age or older, with hemophilia B.
More than 400 people affected by bleeding disorders asked their legislators to take action on the Hemophilia SNF Access Act
We will provide updated guidance if new information has implication for the bleeding disorders community.
On February 28th, Genentech released a statement relating to the supply of Hemlibra as it relates to 2019-nCoV (novel coronavirus).
On February 27th, HFA and NHF released a statement on the recall of VONVENDI lots.
HFA and NHF recognize that recalls can be unsettling for many in the bleeding disorders community. We are in communications with Takeda to obtain additional detailed and timely information.
This is a six-part activity designed to increase healthcare providers' knowledge of the treatment of hemophilia.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car